Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33)

OBJECTIVE: Liraglutide (glucagon-like peptide-1 [GLP-1] receptor agonist) and sitagliptin (dipeptidyl peptidase-4 inhibitor) are approved in Japan for treating type 2 diabetes mellitus (T2DM). We compared the efficacy and safety of adding liraglutide or sitagliptin to a sulfonylurea in Japanese T2DM...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoyama, Hiroki, Hirao, Koichi, Yamaguchi, Kohei, Oishi, Mariko, Lee, Gendai, Yagi, Noriharu, Takamura, Hiroshi, Kashiwagi, Atsunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179438/
https://www.ncbi.nlm.nih.gov/pubmed/25288908
http://dx.doi.org/10.4137/JCM.S16585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179438/
https://www.ncbi.nlm.nih.gov/pubmed/25288908
http://dx.doi.org/10.4137/JCM.S16585

Ejemplares similares